1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth

Executive Summary

•Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. It is estimated that vaccines have reduced the incidence of some diseases by more than xx%.
•Vaccines are now available for prevention of about xx infectious diseases.
•Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next- generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic.
•The vaccine market is segmented into xx categories: infectious disease, cancer, allergy, and others (includes physiological diseases such as diabetes and Alzheimer’s, as well as smoking cessation).
•Infectious disease vaccines—particularly viral vaccines—represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration.
•One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases.
•Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis.
•The market is dominated by xxbiopharmaceutical companies—Sanofi, GlaxoSmithKline (GSK), Merck & Co., Pfizer, and Novartis—that combined hold a nearly xx% global market share. The remaining xx% share is fragmented, represented by more than xx companies—the majority of them clinical-stage.
•Many vaccines are in the pipeline in various clinical stages. Successful outcomes are expected to boost the global market at a CAGR of xx% from 2014 to 2022.
•The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets.
•The vaccine market is perceived as an attractive, profitable venture because of its many opportunities. The overall impact of factors determining profitability is measured in a Porter’s 5 forces analysis.
•While the market is attractive, the intensity of competition is high. It is imperative that companies adopt strategies to meet growing industry demands, such as innovation in or licensing technology platforms for vaccine development or alternative routes toward vaccine administration.
•The vaccine market is witnessing a paradigm shift because of an increasing focus on development of therapeutic vaccines. As a result, the industry is experiencing active collaborations, spin-offs, technological advances, and many active products in the pipeline.

Current Participant Strategies

•Large biopharma corporations’ acquisitions to strengthen their product portfolios in emerging vaccine markets.
•Development of scalable and large-scale manufacturing by outsourcing clinical trials and manufacturing activities.
•Mutually beneficial collaborations and partnerships among companies of all sizes to develop vaccines.

Unmet Needs

•Economical and efficacious prophylactic vaccines in emerging markets.
•Long-term durability of vaccines for HIV, tuberculosis, and other re-emerging diseases.
•New administration routes, such as oral or sublingual.
•Vaccines for physiological disorders and cancer.

Potential Game-changing Strategies

•Technology-dependent development of a new class of vaccines for emerging infectious diseases.
•Development of both prophylactic and therapeutic vaccines to sustain market shares.
•Oral (sublingual, lingual) and needle-free vaccine delivery that increases end-user acceptance.
•Approaches that alleviate safety concerns among end users.

Table Of Contents

Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
Executive Summary
•Executive Summary
•New Market Opportunities
•Recent Market Developments
•Companies to Watch
Methodology and Scope
•Market Segmentation
Introduction
Market Background
•Enabling Technologies
•Regulatory Approval Process
•Global Regulatory Oversight
•Market Revenue Forecast
•Value Chain Analysis
•Porter's 5 Forces Analysis
•Key Gaps
•Vaccine Storage and Logistics
•Vaccine Pricing
Competitive Landscape
•Competitive Landscape Overview
•Product Launch Timeline
•Patent Expirations
•Bacterial Vaccines Segment—Major Ongoing/Recently Completed Clinical Trials
•Viral Vaccines Segment—Major Ongoing/Recently Completed Clinical Trials
•Cancer Vaccines Segment—Major Ongoing/Recently Completed Clinical Trials
Competitive Landscape—Bacterial Vaccines
•Bacterial Vaccines Segment Overview
•Bacterial Vaccines Segment—Key Marketed and Pipeline Products
•Bacterial Vaccines Segment—Key Marketed Products
•Bacterial Vaccines Segment—Key Phase 3 Pipeline Products
•Bacterial Vaccines Segment—Key Phase 2 Pipeline Products
•Bacterial Vaccines Segment—Key Phase 1 Pipeline Products
Competitive Landscape—Viral Vaccines
•Viral Vaccines Segment Overview
•Viral Vaccines Segment—Key Marketed and Phase 3 Pipeline Products
•Viral Vaccines Segment—Key Phase 1 and 2 Pipeline Products
•Viral Vaccines Segment—Key Marketed Products
•Viral Vaccines Segment—Key Phase 3 Pipeline Products
•Viral Vaccines Segment—Key Phase 2 Pipeline Products
•Viral Vaccines Segment—Key Phase 1 Pipeline Products
Competitive Landscape—Parasitic Vaccines
•Parasitic Vaccines Segment Overview
•Parasitic Vaccines Segment—Key Marketed and Pipeline Products
Section
Slide Numbers
•Parasitic Vaccines Segment—Key Phase 3 Pipeline Products
•Parasitic Vaccines Segment—Key Phase 2 Pipeline Products
•Parasitic Vaccines Segment—Key Phase 1 Pipeline Products
Competitive Landscape—Cancer Vaccines
•Cancer Vaccines Segment Overview
•Cancer Vaccines Segment—Key Marketed and Pipeline Products
•Cancer Vaccines Segment—Key Marketed Products
•Cancer Vaccines Segment—Key Phase 3 Pipeline Products
•Cancer Vaccines Segment—Key Phase 2 Pipeline Products
•Cancer Vaccines Segment—Key Phase 1 Pipeline Products
Competitive Landscape—Allergy Vaccines
•Allergy Vaccines Segment Overview
•Allergy Vaccines Segment—Key Marketed and Pipeline Products
•Allergy Vaccines Segment—Key Marketed Products
•Allergy Vaccines Segment—Key Phase 3 Pipeline Products
•Allergy Vaccines Segment—Key Phase 2 Pipeline Products
•Allergy Vaccines Segment—Key Phase 1 Pipeline Products
Competitive Landscape—Other vaccines
•Other Vaccines Segment Overview
•Other Vaccines Segment—Key Pipeline Products
•Other Vaccines Segment—Key Phase 3 Pipeline Products
•Other Vaccines Segment—Key Phase 2 Pipeline Products
•Other Vaccines Segment—Key Phase 1 Pipeline Products
Bacterial Vaccine Product Dashboard
Viral Vaccine Product Dashboard
Parasitic Vaccine Product Dashboard
Cancer Vaccine Product Dashboard
Allergy Vaccine Product Dashboard
Other Vaccine Product Dashboard
Timeline of Key Events
Conclusions
•New Market Opportunities
The Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in Sweden

  • February 2017
    57 pages
  • Infectious Dise...  

    Anti-Infective  

  • Sweden  

    Europe  

View report >

Antiviral Market and Blood Disease Statistics in India

  • February 2017
    4 pages
  • Antiviral  

    Blood Disease  

  • India  

    United States  

View report >

Pathology Statistics in the Netherlands

  • February 2017
    8 pages
  • Pathology  

  • Netherlands  

View report >

Diabetes Statistics

32 hours ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.